Grab a K drug? Baiji Shenzhou PD-1 combined chemotherapy first-line treatment of advanced squamous non-small cell lung cancer phase III data for the first time published

As a result of the new coronary outbreak, the 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO 2020) will be held in the form of an online meeting from May 29 to 31, 2020On May 14th, ASCO's official website published a summary of this year's conference selection, with a large number of new clinical data on innovative therapiesAmong them, the anti-PD-1 antibody drug Terelli-Zthana anti-combination chemotherapy developed by Baiji Shenzhou was used to treat first-line patients with squamous non-small cell lung cancer (NSCLC) in Phase 3 clinical trials (BGB-A317-307 study) data for the first time disclosed to the outside worldAs one of the representative drugs for anti-PD-1/PD-L1 therapy, the KEYNOTE-407 study of Pembrolizumab (K drug) is a major advance in immunotherapy in the field of first-line squamous non-small cell lung cancerHowever, due to the small number of chinese patients enrolled in the study, a total of 125 chinese patients were included, of which the number of patients in the Pablo Pearl mono-anti-joint chemotherapy group was only 65 cases, and the first-line Chinese squamous non-small cell lung cancer patients using immunojoint therapy in the large sample of 3 study data is still blankThe BGB-A317-307 study pilot designAccording to the latest summary, the BGB-A317-307 study included 360 Chinese patients, of whom about two-thirds (239 cases) were treated with the Combination Chemotherapy program of Tirelli-ZumaThis is the first successful large-scale 3-stage registered clinical study of advanced squamous non-small cell lung cancer in Chinese groups, and the only one with the largest sample size ever publishedfrom the data disclosed in this summary, The telre-zonita-resistant chemotherapy is used to treat first-line squamous non-small cell lung cancer, compared with traditional chemotherapy regimens, and has brought good clinical benefits to patients with advanced squamous non-small cell lung cancer in China, as shown in:1Significantly reduces the risk of disease progression in patients, prolongs progression survival time (PFS), of which Treli-Z-Mono-anti-joint white purple-and-ka-platinum Group mPFS reached 7.6 months, the risk of disease progression significantly reduced by 52% (P 0.0001), the mPFS of the Telli beads mono-anti-cosiphol-caplatinum group also reached 7.6 months, the risk of disease progression decreased by 48% (P-0.0001), and the chemotherapy control group mPFS was only 5.5 months2Nearly 75% of the patients achieved objective remission, compared with the chemotherapy group less than 50% of the remission rate, the benefit of the patient increased by 50%, of which the objective mitigation rate (ORR) of the direlizumab mono-anti-combined white purple-ca-platinum group reached 74.8%, the ORRR of the Tyrey-Single-Anti-Union Yew-Ca-Platinum group reached 72.5%, while the chemotherapy control group ORRR was only 49.6%3The patient's remission duration (DoR) was increased to about 2 times the single-use chemotherapy regimen, with mDOR in the Delli-Zona-mono-joint white-purple-ca-platinum group reaching 8.6 months, the mDOR of the Telli-Pearl mono-anti-union yew alcohol-caplatinum group reaching 8.2 months, and the mDoR in the chemotherapy control group only 4.2 monthsAt present, the results of the medium-term analysis, the median follow-up 8.6 months, with the extension of follow-up time, 307 studies of the efficacy of the TelliZumathan treatment group is expected to further improve In addition, the overall tolerance and safety of patients performed well in the treatment of tyreli beads in combination with sequoia/albumin yew alcohol plus caplatinum in addition to , four clinical trials in the field of lung cancer are currently being conducted simultaneously around the world In addition to the new indications application for first-line squamous non-small cell lung cancer that has been accepted by NMPA, the BGB-A317-304 study for the treatment of first-line non-squamous non-small cell lung cancer has also been published positive results in April this year In addition to the 307 and 304 studies, the global multi-center 3 registered clinical study (303 study) of patients with advanced two/third-line NSCLC treatment of Terrey Zuma single anti-single drug therapy has completed global patient intake, and another joint platinum-containing double-drug chemotherapy treatment for first-line wide-term small cell lung cancer (SCLC) patients (312 studies) is also under way On May 12, Baiji Shenzhou reported its first-quarter 2020 results, which showed a strong performance for Mr Reilly,' which generated $20.53 million in sales in less than a month since commercial is available in China in March For other PD-1 drugs in the first quarter of the market sales, the performance of Thereli Sudonta in the first quarter after the market fully demonstrated its competitiveness With the approval of the second indication-resistant urinary tract cancer in China in early April this year, its market has been further expanded, the preliminary estimate of The Reilly Pearl Mono-anti sales revenue for the whole year is expected to exceed 1 billion yuan source: of Biological
Exploration